Sutter Bay Hospitals

9 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Dec 2030

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 21, 2027
The maintenance fee for Methods and compositions for treating cancer (US 9,084,771) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
1 fee due Jul 7, 2027
The maintenance fee for Falz for Use as a Target for Therapies to Treat Cancer (US 10,526,662) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
1 fee due Aug 9, 2027
The maintenance fee for Resorcinol derivatives (US 9,254,272) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 9,084,771	Methods and compositions for treating cancer In force Term ends Dec 27, 2030 · From the USPTO record	In force	Term ends Dec 27, 2030	From the USPTO record
US 10,202,322	Resorcinol Derivatives In force Term ends Nov 30, 2032 · Medium confidence	In force	Term ends Nov 30, 2032	Medium confidence
US 11,260,043	Methods and compositions for treating cancer In force Term ends Jun 2, 2033 · From the USPTO record	In force	Term ends Jun 2, 2033	From the USPTO record
US 9,254,272	Resorcinol derivatives In force Term ends Jul 26, 2033 · From the USPTO record	In force	Term ends Jul 26, 2033	From the USPTO record
US 11,142,796	MIR-18B for use as a marker of cancer progression and target for therapies to treat cancer In force Term ends Sep 19, 2033 · From the USPTO record	In force	Term ends Sep 19, 2033	From the USPTO record
US 10,526,662	Falz for Use as a Target for Therapies to Treat Cancer In force Term ends Mar 15, 2034 · High confidence	In force	Term ends Mar 15, 2034	High confidence
US 9,920,377	Falz for Use as a Target for Therapies to Treat Cancer In force Term ends Aug 5, 2034 · High confidence	In force	Term ends Aug 5, 2034	High confidence
US 11,332,792	Mitochondrial DNA mutation profile for predicting human health conditions and disease risk and for monitoring treatments In force Term ends Apr 6, 2037 · From the USPTO record	In force	Term ends Apr 6, 2037	From the USPTO record
US 12,612,358	Resorcinol-Based Compounds and Uses Thereof In force Term ends Jan 15, 2043 · High confidence	In force	Term ends Jan 15, 2043	High confidence

Also on record, not counted in the 9: 1 patent in force now held by others · 11 lapsed for an unpaid fee · 1 ended at full term · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

Every application published under this name has become a patent.